Radiologists overestimatemammo malpractice threat
The perceived threatof medical malpracticeclaims makes a biggerimpression on radiologiststhan is warrantedby the actual risk of litigation.
The perceived threat of medical malpractice claims makes a bigger impression on radiologists than is warranted by the actual risk of litigation.
Dr. John F. Dick III and colleagues at Dartmouth mailed surveys in 2006 to 118 radiologists who participated in any of three registries associated with the Breast Cancer Surveillance Consortium in Colorado, New Hampshire, and western Washington. They compared findings with those of a similar survey performed in 2002. Researchers found that the perceived risk of being sued is four times higher than the reported rate of malpractice claims.
In 2006, radiologists estimated that they had a 35% chance of facing a mammography- related malpractice suit in the next five years. In 2002, they rated the likelihood at 41%, but actual claim reports reached 8% in 2002 and 10% in 2006 (AJR 2009;192:327-333).
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
SNMMI: Botox May Facilitate Relief from Dry Mouth Side Effect of PSMA-Targeted Radiopharmaceuticals
June 25th 2025For patients being treated with radiopharmaceutical agents for metastatic prostate cancer, the combination of botulinum toxin and an anti-nausea patch led to a 30 percent reduction in PSMA uptake in the salivary glands, according to preliminary research findings presented at the SNMMI conference.
SNMMI: Can 18F-Fluciclovine PET/CT Bolster Detection of PCa Recurrence in the Prostate Bed?
June 24th 2025In an ongoing prospective study of patients with biochemical recurrence of PCa and an initial negative PSMA PET/CT, preliminary findings revealed positive 18F-fluciclovine PET/CT scans in over 54 percent of the cohort, according to a recent poster presentation at the SNMMI conference.
